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Reverse micelles are thermodynamically stable systems, with a capacity to encapsulate 
hydrophilic molecules in their nanosized core, which is smaller than the core generally 
obtained with water-in-oil-emulsion droplets. Herein, we present a simple technique for 
the preparation of poly(ethylene glycol)-block-polylactide (PEG-b-PLA) nanocapsules 
encapsulating a hydrophilic photosensitizer (indocyanine green, ICG), which exploits 
reverse micelle formation and subsequent emulsion-solvent diffusion. We establish the 
effect of the PEG-b-PLA composition and the co-surfactant volume on the diameter and 
water content of the reverse micelles. We demonstrate that the composition of 
PEG-b-PLA affects also the diameter and encapsulation efficiency of the resulting 
nanocapsules. We show that the ICG-laden nanocapsules fabricated under the most 
optimal conditions have a diameter of approximately 100 nm and an ICG encapsulation 
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efficiency of 58%. We believe that the method proposed here is a promising step 
towards the preparation of hydrophilic drug-laden polymer nanocapsules with a small 
diameter and therefore suitable for use in drug delivery applications based on enhanced 
permeability and retention (EPR) effect-driven passive targeting. 
1. Introduction 
Design and development of drug delivery systems for the efficient transport of drugs to 
a target site in the human body, with control over the drug release behavior, have 
received significant attention. Efficient delivery of drugs can be achieved using a 
multitude of suitable drug vehicles, including liposomes [1-3], polymer micelles [4-6], 
and polymer nanoparticles [7-10]. Among these options, biodegradable polymer 
nanoparticles, such as poly(ethylene glycol)-block-polylactide (PEG-b-PLA) 
nanoparticles with a PEG corona, have been considered as one of the most promising 
materials for drug delivery. The PEG corona layer prevents the adsorption of proteins 
and phagocytic cells on the nanoparticle surface, thereby extending significantly their 
potential blood circulation time [11,12]. In addition, the kinetics of the drug release 
from the nanoparticles can be controlled by the composition of the PLA matrix [13]. 
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 To date, PEG-b-PLA nanoparticles have been generally prepared by either 
emulsion-solvent evaporation method [14-18] or emulsion-solvent diffusion method 
[19-24]. Both of these nanoparticle-forming processes, however, are based on the 
removal of organic solvent from the precursor emulsion droplets in which the 
PEG-b-PLA nanoparticles and the drugs are dissolved. The core of the PEG-b-PLA 
nanoparticles comprises hydrophobic PLA and, therefore, these techniques are suitable 
for the encapsulation of hydrophobic drugs only. In contrast, the encapsulation of 
hydrophilic drugs in nanoparticles [25-27] has generally employed multiple emulsion 
systems such as water-in-oil-in-water (W/O/W) emulsions. The resulting nanoparticles 
are classified as “nanocapsules,” with an inner aqueous core, capable of dissolving 
hydrophilic drugs and an external polymeric shell that serves as a barrier to diffusion. 
However, the PEG-b-PLA nanocapsules obtained using such multiple emulsion systems 
generally produce particles with a large diameter (over 200 nm) because of the 
multi-step nature of the emulsification process. Enhanced permeability and retention 
(EPR) effect is essential for achieving efficient drug accumulation around cancerous 
tumors, however, this effect is expected only for nanocarriers that are less than ca. 200 
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nm in size and show a prolonged circulation property [28]. Therefore, there is a growing 
interest in developing techniques for the preparation of PEG-b-PLA nanocapsules with a 
diameter <200 nm, and thus a high encapsulation efficiency of hydrophilic drugs. 
 In this paper, we propose a novel technique for obtaining PEG-b-PLA 
nanocapsules with a diameter of ca. 100 nm and a nonionic PEG surface, with a 
capacity to encapsulate hydrophilic photosensitizer (indocyanine green (ICG)). Fig. 1 
shows the proposed method for the nanocapsule preparation, based on reverse micelle 
formation and oil-in-water (O/W) emulsion-solvent diffusion. To begin with, oil-soluble 
PEG-b-PLA (o-PEG-b-PLA) reverse micelles are prepared by dissolving o-PEG-b-PLA 
in a mixture of ethyl acetate (EA) and isopropanol (IPA) as the co-surfactant, and 
allowing this mixture to come into contact with pure water. In this first step, 
amphiphilic o-PEG-b-PLA molecules, dissolved in the organic phase, assemble to give 
reverse micelles with extremely small aqueous cores. In the second step, ICG is added 
to the organic solution, where the nanoscale aqueous core of the prepared reverse 
micelles facilitates its dissolution. In the third step, the organic phase containing the 
reverse micelles is emulsified with an aqueous solution containing water-soluble 
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PEG-b-PLA (w-PEG-b-PLA) by ultrasonication, which generates O/W emulsion 
nanodroplets. In the final step, the nanoemulsion is diluted with a large of pure water. 
Because of the high solubility of EA in water (8.7 wt% at 20 °C), the EA present in the 
droplet diffuses quickly into the external aqueous solution, resulting in the precipitation 
of ICG-laden PEG-b-PLA nanocapsules. The key feature of our method is the use of a 
reverse micelle system to drive the nanocapsule formation, as well as the incorporation 
of ICG as a hydrophilic molecule in these nanocapsules. Reverse micelles have the 
capacity to spontaneously incorporate hydrophilic molecules and their size is 
significantly smaller than that of typical water-in-oil (W/O) droplets. Therefore, we 
expect that this system will lead to improvements in the encapsulation efficiency of 
hydrophilic drugs and reduce the diameter of the resulting nanocapsules. In addition, 
PEG-b-PLA molecules that do not participate in forming reverse micelles in the O/W 
emulsion nanodroplets can adsorb to the O/W interface during preparation, and thus the 
resulting nanocapsules would have a nonionic PEG layer on their surfaces, which 
results in the enhancement of their prolonged circulation property in vivo. In this study, 
we focused specifically on investigating the effect of the preparation conditions (such as 
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the composition of o-PEG-b-PLA and the diameter of the reverse micelles) on the 
diameter of the resulting nanocapsules and their ability to encapsulate ICG. To the best 
of our knowledge, this is the first study to use polymer-based nanocapsules, fabricated 
using reverse micelles as the carrier for hydrophilic molecules. 
 
2. Materials and methods 
2-1. Materials 
 
Poly(ethylene glycol) monomethyl ether (mPEG, Mn = 4,000, Mw/Mn = 1.06) was 
kindly supplied by NOF (Japan) and used as received. D,L-Lactide was purchased from 
Purac (Netherlands) and recrystallized from toluene, followed by drying under reduced 
pressure overnight before use. Stannous octoate (Sn(Oct)2), ethyl acetate (EA), 
chloroform (CHCl3), isopropyl alcohol (IPA), and n-hexane were purchased from Wako 
Pure Chemical Industries, Ltd. (Japan). Indocyanine green (ICG) was purchased from 
Tokyo Chemical Industry (Japan) and tetrahydrofuran (THF) was purchased from 
Kishida Chemical Co., Ltd. (Japan). Chloroform-d1 (CDCl3) was obtained from 
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Sigma-Aldrich (Japan). Ultrapure water was produced using a Millipore Milli-Q® 
purification system (EMD Millipore Corporation, USA). 
 
2-2. Synthesis of PEG-b-PLA 
 
PEG-b-PLA was synthesized by a ring-opening polymerization of D,L-lactide using 
mPEG as the initiator and Sn(Oct)2 as the catalyst. Specifically, D,L-lactide, mPEG, and 
Sn(Oct)2 (80 mg/mL) in toluene were introduced into a glass ampule, which was sealed 
in vacuo and heated in an oil bath at 130 °C for 24 h. Then, the ampule was broken and 
the reaction mixture was dissolved in chloroform (50 mL) and the precipitation of the 
desired polymer was achieved by the addition of n-hexane (400 mL) through a cotton 
filter. The precipitated polymer was isolated by decantation, washed with IPA, and dried 
in an oven under reduced pressure at 40 °C. The molecular weight distribution (Mw/Mn) 
of the prepared polymer samples was measured by gel permeation chromatography 
(GPC, HLC-8220GPC, TOSOH, Japan) at 40 °C, equipped with a refractive index 
detector and various columns (TSKguard column SuperH-H, TSKgel SuperHM-H, and 
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TSKgel SuperH2000, TOSOH, Japan). Throughout the GPC analysis, THF was used as 
the eluent at a flow rate of 0.6 mL/min, and the calibration curve was obtained using 
polystyrene standards. The chemical structure of the fabricated polymers was confirmed 
by 1H NMR spectroscopy. The NMR analysis was carried out using a JEOL FT NMR 
System (JMN-AL300, JEOL, Japan) at room temperature in CDCl3. The number 
number-average molecular weights (Mn) of the polymer samples were calculated from 
the corresponding 1H NMR spectra. 
 
2-3. Preparation and physicochemical characterization of o-PEG-b-PLA reverse 
micelles 
 
EA solutions (5 mL each) containing o-PEG-b-PLA (3 wt%) with a varying 
hydrophile-lipophile balance (HLB) were prepared, followed by addition of IPA (0.1–
2.0 mL). Pure water (10 mL) was slowly introduced into each sample. The samples 
were shaken horizontally for 24 hours at 100 rpm at room temperature, which lead to 
the formation of reverse micelles in the organic phase. The organic phase was gently 
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isolated from each sample and the water content in this organic phase was measured 
using a Karl Fischer Titrator (MKA-610, Kyoto Electronics, Japan). The hydrodynamic 
diameter of the reverse micelles was measured by dynamic light scattering (DLS) using 
Zetasizer Nano ZS (Malvern instruments, UK). 
 
2-4. Preparation of ICG-laden o-PEG-b-PLA nanocapsules 
 
Polymeric nanocapsules encapsulating ICG were prepared by a two-step process, where 
the ICG was first solubilized within the reverse micelles, followed by emulsion-solvent 
diffusion. First, several samples of o-PEG-b-PLA (3 wt%) with a different HLB value 
were each dissolved in EA (4 mL). A different amount of IPA, used as the co-surfactant, 
was added into the prepared organic solutions, followed by slow addition of pure water 
(10 mL) to give two-phase systems. The samples were shaken for 24 hours at 100 rpm 
at room temperature, which facilitated extraction of the aqueous phase into the organic 
phase and formation of reverse micelles in the organic phase. The organic phase (2 mL) 
was carefully isolated form each sample. ICG (2 mg), which is insoluble in both EA and 
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IPA but soluble in water, was added to the prepared organic phases. Water-soluble 
w-PEG-b-PLA (5 wt%) was dissolved in a NaOH aqueous solution (5 mL, pH = 12.0) 
by ultrasonication (at 20°C, 160W, 20 sec). Each organic polymer phase, now 
comprising the solubilized ICG, was mixed with the prepared aqueous w-PEG-b-PLA 
solution, resulting in an O/W emulsion. The prepared emulsion was diluted with a 
NaOH aqueous solution (40 mL, pH = 12.0), thereby inducing diffusion of EA into the 
continuous aqueous phase, while keeping ICG in the dispersed phase and subsequent 
precipitation of o-PEG-b-PLA nanocapsules. The nanocapsules were purified by 
centrifugation (82,000 g for 15 min, 3 runs), and freeze-dried overnight, affording the 
nanocapsules as a green powder. All steps of the preparation process were carried out in 
darkness in order to prevent the photo-degradation of ICG. The morphology of the 
prepared nanocapsules after freeze-drying was observed by means of a scanning 
electron microscope (SEM, S-4700, Hitachi Ltd., Japan) at a voltage intensity of 1 kV. 
The prepared nanocapsule samples were sputter-coated (E-1030 Ion-Sputter, Hitachi 
Ltd., Japan) with Pd/Pt in order to reduce the sample charging. 
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2-5. Physicochemical characterization of ICG-laden PEG-b-PLA nanocapsules 
 
The hydrodynamic diameter and the zeta potential of the prepared nanocapsules was 
determined by DLS using Zetasizer Nano ZS (Malvern instruments, UK) at 25 °C. The 
nanocapsule samples were suspended in water and sonicated thoroughly before the 
measurement in order to produce a homogeneous suspension. The measured 
nanocapsule sizes were determined as the average value of 15 runs. The experimental 
values were calculated as the average of three different nanocapsule formulations. The 
zeta potential values of the nanocapsules were determined as the average 
value of 100 runs. In order to determine the encapsulation efficiency of ICG in the 
nanocapsules, a sample of the freeze-dried nanocapsules (2 mg) was dissolved in acetic 
acid (2 mL) and the solution was analyzed by UV-Vis spectroscopy (U-2000A, Hitachi, 
Japan) at a wavelength of 787 nm. The concentration of ICG in the sample was 
determined by comparison to a standard curve. All measurements were carried out 
under reduced lighting and the instrument operating conditions were kept constant. 
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3. Results and discussion 
 
3-1. Synthesis and characterization of PEG-b-PLA block copolymers 
 
We synthesized PEG-b-PLA diblock copolymers by a ring-opening polymerization of 
D,L -lactide, using mPEG as the macroinitiator. PEG is a hydrophilic and biocompatible 
polymer that has been used widely as a non-inflammatory modifier for proteins and 
drugs, whereas PLA is a hydrophobic and biodegradable polymer that has been used 
predominantly as a matrix in the fabrication of biomaterials. The PEG-b-PLA diblock 
copolymers synthesized in this study were characterized by 1H NMR spectroscopy and 
GPC analysis (Fig. S1), and a summary of the results is shown in Table 1. The 
number-average molecular weight (Mn) and the molecular weight distribution (Mw/Mn) 
were determined from the 1H NMR spectra and GPC analysis, respectively. In this study, 
we synthesized six types of PEG-b-PLA diblock copolymers with different length of 
PLA. The variation in the PLA length was achieved by changing the molar ratio of the 
monomer (D,L-lactide) to the initiator (PEG) during the polymerization reaction. The 
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obtained diblock copolymers can be classified into two groups, depending on their 
solubility: water-soluble PEG-b-PLA (w-PEG-b-PLA) and oil-soluble PEG-b-PLA 
(o-PEG-b-PLA). The water-soluble w-PEG-b-PLA (Mn = 4,700; Mn PEG = 4,000; Mn 
PLA = 700) with an HLB of 18.2 exhibits excellent surface activity between an EA and 
water (O/W) interface [29] and was therefore used as a polymeric surfactant to stabilize 
the emulsion. The five different remaining oil-soluble o-PEG-b-PLA copolymers (Table 
1, Mn = 12,700–42,400; Mn PEG = 4,000; Mn PLA = 8,700–38,400) with an HLB in the 
range of 1.89–6.30 were used as the matrix in the formation of reverse micelles and 
nanocapsules. 
 
3-2. Effect of the co-surfactant content on the diameter of the reverse micelles 
 
Owing to the hydrophobic nature of the PLA segment, amphiphilic PEG-b-PLA 
copolymers can self-assemble in aqueous solutions to form micelles. Similarly, because 
of the hydrophilic nature of the PEG segment, PEG-b-PLA copolymers have the 
capacity to form reverse micelles in solvents. Reverse micelles are thermodynamically 
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stable systems with the capacity to spontaneously solubilize hydrophilic drugs within 
their nanosized core. In contrast, W/O emulsions are generally unstable, leading to the 
coalescence of all droplets over time. Thus, the use of a reverse micellar solution as the 
dispersed phase in the formation of hydrophilic drug-laden nanocapsules presents an 
efficient tool for controlling the nanocapsule diameter, compared to the use of W/O 
emulsions. The diameter of reverse micelles is determined by the amount of the 
co-surfactant and the compositions of the copolymer employed in their formation. 
Therefore, we first examined the effect of the co-surfactant content on the diameter of 
the reverse micelles. In this study, isopropyl alcohol (IPA) with a secondary alcohol 
group was used as the co-surfactant in order to enhance the stability of the reverse 
micelles [30]. The reverse micelles were prepared by shaking 5 mL of EA solution 
containing 3 wt% of o-PEG-b-PLA and IPA (0.1, 0.5, 1.0, 1.5 or 2.0 mL), and 10 mL of 
pure water for 24 hours. We observed that the organic phase turned slightly cloudy after 
24 hours, at which point we used the organic phase to determine the diameter of the 
reverse micelles using DLS. 
 Fig. 2 shows the effect of the quantity of the co-surfactant (IPA) present in the 
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mixture on the diameter of the reverse micelles obtained in the EA phase. We prepared 
the reverse micelles using o-PEG-b-PLA samples with different HLB values. The 
experiment employing the least hydrophophilic o-PEG-b-PLA-1, with an HLB of 1.89, 
showed that the diameter of the reverse micelles in EA reaches a minimum value at 1 
mL of IPA, and then increases sharply with increasing amount of IPA (up to 2 mL). 
More specifically, in the presence of 0.1–0.5 mL IPA, the o-PEG-b-PLA molecules were 
found to form large polymer aggregates (d > 300 nm). Increasing the IPA quantity to 1 
mL resulted in the formation of the smallest reverse micelles, with a diameter of less 
than 100 nm. This result indicates that 1 mL of IPA is the quantity of co-surfactant that 
is the most suitable for the formation of stable reverse micelles with a small diameter. 
The steep increase in the reverse micelle size in the presence of more than 1 mL of IPA 
might indicate a reduced solubility of the PLA segments of o-PEG-b-PLA in the 
mixture of EA and IPA, thereby destabilizing the reverse micelles. Formation of reverse 
micelles using more hydrophophilic o-PEG-b-PLA-5, with an HLB of 6.30, revealed 
that the diameter of the reverse micelles remains fairly constant in the 0.1–1 mL range 
of IPA, and increases when the quantity of IPA is increased from 1 mL to 2 mL. These 
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results show that formation of small reverse micelles with o-PEG-b-PLA-5 requires a 
smaller quantity of IPA, compared to o-PEG-b-PLA-1. Using these experiments, we 
determined that the reverse micellar system that employs the IPA co-surfactant at 1 mL 
is the most suitable system for the preparation of small reverse micelles from 
o-PEG-b-PLA. Therefore, all experiments in the subsequent sections were carried out at 
using a fixed amount of IPA (1 mL) in the organic phase. 
 
3-3. Effect of o-PEG-b-PLA composition on the properties of the reverse micelles 
 
In the next step, we examined the relationship between the composition of 
o-PEG-b-PLA and the reverse micelle size and the water content. The reverse micelles 
were prepared by shaking 10 mL of pure water with 1 mL of IPA and 5 mL of EA 
solution containing 3 wt% of o-PEG-b-PLA with different HLB values for 24 hours. In 
these experiments, a higher HLB value corresponds to a lower ratio between the length 
of PLA and the PEG length. Fig. 3 shows the changes in the measured diameter of the 
reverse micelles and the water content in the reverse micellar solutions as a function of 
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the HLB value of o-PEG-b-PLA. The reverse micelle diameter was found to decrease 
together with an increasing value of HLB. In contrast, the water content in the reverse 
micellar solution exhibited an increase with increasing HLB values. Most likely, the 
reduction in the reverse micelle size can be attributed to the shorter length of the PLA 
segment in the reverse micelle core. The increase in the water content, on the other hand, 
probably stems from the increase in the proportion of PEG in the system. The molecular 
weight of o-PEG-b-PLA decreases with an increasing HLB value, which represents an 
increase in the content of the hydrophilic PEG in the system relative to the hydrophobic 
PLA. The reverse micelles were prepared using a given weight% of o-PEG-b-PLA and, 
therefore, an increase in the HLB value of o-PEG-b-PLA corresponds to an increase in 
the molar concentration of o-PEG-b-PLA in the organic phase. The PEG segments in 
o-PEG-b-PLA have a high affinity for water molecules. Expectedly, therefore, the water 
content in the reverse micellar solution increased with an increasing molar 
concentration of the PEG segments in the system. These results demonstrate that the 
HLB value of the employed o-PEG-b-PLA affects significantly the reverse micelle size 
and the water content in the reverse micellar solution. In summary, we established 
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successfully that employing the o-PEG-b-PLA with the highest HLB value affords 
reverse micelles with the smallest diameter. 
 
3-4. Effect of o-PEG-b-PLA composition on the nanocapsule diameter and ICG 
encapsulation efficiency 
 
ICG is a water-soluble carbocyanine dye that absorbs and fluoresces strongly in the 
near-infrared region of the electromagnetic spectrum, exhibiting an absorption and 
emission maxima at 780 and 820 nm, respectively. This molecule is frequently used as a 
contrast agent in biology [31-33] and as a photosensitizer in photodynamic therapy 
(PDT), where it produces heat and toxic chemical species such as singlet oxygen, 
superoxide anions, and hydroxyl radicals to destroy cancerous cells and tissues [34,35]. 
Incorporation of ICG in PEG-b-PLA nanocapsules having approximately 100 nm in 
diameter and a PEG surface would be able to enhance the stability of ICG in vivo and 
deliver it to the target cancerous cells and tissues through EPR effect, which would 
allow recipients for PDT to avoid critical side effects such as photodermatosis. We thus 
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prepared ICG-incorporating PEG-b-PLA nanocapsules using reverse micelle formation, 
followed by emulsion-solvent diffusion. Following the preparation of an EA solution 
containing the reverse micelles, 2 mg of ICG was dissolved in 2 mL of the organic 
phase. We found that while a control EA solution lacking the reverse micelles was not 
capable of dissolving ICG, the EA solution containing the reverse micelles dissolved 
ICG completely. The EA solution, now containing the dissolved ICG, was mixed with 5 
mL of an aqueous w-PEG-b-PLA solution (pH 12) by sonication, resulting in an O/W 
emulsion. The emulsion solution was diluted with 40 mL of a basic aqueous solution 
(pH 12), which induced the diffusion of the EA into the aqueous phase and precipitation 
of the nanocapsules.  
 Fig. 4 shows the changes in the hydrodynamic diameter of the nanocapsules 
after solvent diffusion as a function of the HLB of the employed o-PEG-b-PLA, at a 
fixed volume of IPA (1 mL). The results in Fig. 4 clearly show that the hydrodynamic 
diameter decreases with an increasing o-PEG-b-PLA HLB value—an outcome, which is 
in good agreement with the HLB-dependent change in the size of reverse micelles, 
discussed previously in Fig. 3. To evaluate the surface properties of the nanocapsules, 
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we performed the zeta potential measurement of the nanocapsules. As shown in Table 2, 
we found that the zeta potential values of the obtained nanocapsules were slightly 
negative in the range of -2 mV to -11 mV, and that these values were in good 
accordance with those of nanoparticles surface modified by PEG in the previous report 
[36]. Combined together, these results suggest that decreasing the size of the reverse 
micelles is essential in order to obtain nanocapsules with a smaller diameter, and 
indicate that some part of PEG portions of o-PEG-b-PLA in the nanocapsules would be 
organized near the surface of the nanocapsules.  
 After the solvent diffusion, the nanocapsules were purified with pure water and 
collected by centrifugation. Fig. 5 shows the appearance of the nanocapsule dispersion 
after centrifugation. The green color of the resulting supernatant in the nanocapsule 
dispersions, prepared using o-PEG-b-PLA with an HLB value of 5.48 and 6.30, is 
indicative of ICG leakage during the centrifugation process. This leakage might be 
caused by the shorter length of the PLA segments in the employed o-PEG-b-PLA, and 
was significantly less noticeable in the dispersions with HLB values below 5.48. The 
shorter PLA length is associated with a shorter diffusion distance between the aqueous 
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core of the nanocapsules and the external aqueous phase [37]. Fig. 6 shows the 
encapsulation efficiency of ICG in the resulting nanocapsules, as determined by UV-Vis 
spectroscopy. We found that the highest encapsulation efficiency of 58.4% was 
achieved in the nanocapsules prepared using o-PEG-b-PLA-4 with an HLB of 4.28. 
From these results, we determined that o-PEG-b-PLA-4 is the most suitable material for 
both the fabrication of nanocapsules with a diameter around 100 nm and for reducing 
the leakage of ICG molecules during the centrifugation. 
 
4. Conclusions 
We described and successfully demonstrated a simple technique for the preparation of 
PEG-b-PLA nanocapsules incorporating a hydrophilic photosensitizer, employing (i) 
reverse micelle formation and (ii) solvent diffusion. This technique differs significantly 
from the conventional W/O/W emulsion-solvent evaporation method. By tuning the 
composition of o-PEG-b-PLA and the quantity of the co-surfactant in the reverse 
micelle system, we were able to generate polymer nanocapsules with a diameter of less 
than 100 nm. Although further research investigating the control over the release 
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kinetics of the incorporated drug is required, we believe that the technique proposed 
here is a powerful and a facile method for preparing hydrophilic drug-laden polymer 
nanocapsules that can be applied to drug delivery systems based on EPR 
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Table 1 Characterization of the synthesized PEG-b-PLA copolymers, each with a 
different HLB value. 
Sample 
Mn 
Mw/Mn HLB Solubility 
Diblock PLA PEG 
o-PEG-b-PLA-1 42,400 38,400 4,000 1.08 1.89 Oil-soluble 
o-PEG-b-PLA-2 28,700 24,700 4,000 1.32 2.79 Oil-soluble 
o-PEG-b-PLA-3 18,700 14,700 4,000 1.49 4.28 Oil-soluble 
o-PEG-b-PLA-4 16,800 12,800 4,000 1.47 5.48 Oil-soluble 
o-PEG-b-PLA-5 12,700 8,700 4,000 1.28 6.30 Oil-soluble 





Fig. 1 A diagram illustrating the preparation of ICG-laden PEG-b-PLA nanocapsules by 




   
Fig. 2 Average diameter of reverse micelles fabricated using o-PEG-b-PLA with an 
HLB of 1.89 (full black circles) or 6.30 (empty white circles) in the organic phase, and 
an increasing amount of IPA (0–2 mL), as determined by dynamic light scattering. The 
volume of EA was fixed at 5 mL. 
 
 
Fig. 3 Average diameter of the reverse micelles (full black circles) and the water content 
in the reverse micellar solutions (empty white squares) determined as a function of the 





Fig. 4 Relationship between the HLB value of o-PEG-b-PLA and the diameter of the 
resulting nanocapsules. 
 
Table 2 Zeta potential values of the resulting nanocapsules composed of PEG-b-PLA 
having a different HLB value. 
Nanocapsule HLB Zeta potential [mV] 
o-PEG-b-PLA-1 1.89 -10.1 
o-PEG-b-PLA-2 2.79 -7.2 
o-PEG-b-PLA-3 4.28 -4.3 
o-PEG-b-PLA-4 5.48 -2.9 






Fig. 5 Appearance of the nanocapsule dispersion after centrifugation, showing the 
increasing leakage of ICG into the supernatant with increasing value of HLB (left to 
right). 
  
Fig. 6 Encapsulation efficiency of ICG determined for nanocapsules prepared using 
o-PEG-b-PLA with different values of HLB. 
 
 
